COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
Details
Publication Year 2024-10,Volume 131,Issue #6,Page 1005-1013
Journal Title
British Journal of Cancer
Publication Type
Research article
Abstract
BACKGROUND: To determine whether the addition of durvalumab (anti-PD-L1) and oleclumab (anti-CD73) to standard-of-care treatment (FOLFOX and bevacizumab) enhances the anti-tumour effect in patients with metastatic colorectal cancer (mCRC). METHODS: COLUMBIA-1 (NCT04068610) was a Phase Ib (feasibility; Part 1)/Phase II (randomised; Part 2) trial in patients with treatment-naïve microsatellite stable mCRC. Patients in Part 2 were randomised to receive standard-of-care (control arm) or standard-of-care plus durvalumab and oleclumab (experimental arm). Primary objectives included safety and efficacy. RESULTS: Seven patients were enrolled in Part 1 and 52 in Part 2 (n = 26 in each arm). Grade ≥3 treatment-emergent adverse events (TEAE) occurred in 80.8% and 65.4% of patients in the control and experimental arms of Part 2, respectively, with 26.9% and 46.3% experiencing serious TEAEs. The confirmed objective response rate (ORR) was numerically higher in the experimental arm compared with the control arm (61.5% [95% confidence interval (CI), 40.6-79.8] vs 46.2% [95% CI, 26.6-66.6]) but did not meet the statistically significant threshold in either arm. CONCLUSION: The safety profile of FOLFOX and bevacizumab in combination with durvalumab and oleclumab was manageable; however, the efficacy results do not warrant further development of this combination in patients with microsatellite stable mCRC. REGISTRATION: NCT04068610.
Publisher
Springer Nature
Keywords
Humans; *Colorectal Neoplasms/drug therapy/genetics/pathology; Female; Male; *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse; effects/administration & dosage; *Bevacizumab/administration & dosage/adverse effects; Middle Aged; Aged; Adult; *Antibodies, Monoclonal/administration & dosage/adverse effects/therapeutic use; Leucovorin/administration & dosage/therapeutic use/adverse effects; Fluorouracil/administration & dosage/adverse effects; Organoplatinum Compounds/administration & dosage/adverse effects/therapeutic use; Neoplasm Metastasis; Aged, 80 and over
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1038/s41416-024-02796-3
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-10-01 07:37:03
Last Modified: 2024-10-01 07:37:20

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙